1.0Public Citizenhttps://www.citizen.orgDiane Krauthamerhttps://www.citizen.org/author/dkrauthamer/rich600338<blockquote class="wp-embedded-content" data-secret="YQzxD9o7nK"><a href="https://www.citizen.org/article/testimony-before-the-fdas-endocrinologic-and-metabolic-drugs-advisory-committee-regarding-liraglutide-victoza-for-cardiovascular-risk-reduction/">Testimony Before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding Liraglutide (Victoza) for Cardiovascular Risk Reduction</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.citizen.org/article/testimony-before-the-fdas-endocrinologic-and-metabolic-drugs-advisory-committee-regarding-liraglutide-victoza-for-cardiovascular-risk-reduction/embed/#?secret=YQzxD9o7nK" width="600" height="338" title="“Testimony Before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding Liraglutide (Victoza) for Cardiovascular Risk Reduction” — Public Citizen" data-secret="YQzxD9o7nK" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript"> /* <![CDATA[ */ /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); /* ]]> */ </script> Public Citizen testified against the additional approval of liraglutide (Victoza) for reducing cardiovascular risk in diabetes patients because the clinical trial to support such approval failed to show any benefit in the 2,500 American subjects in the trial. The study only showed a significant benefit in non-U.S. subjects.https://www.citizen.org/wp-content/uploads/public_citizen_shared_link.jpg1200628